Introduction：Basic information about CAS 31645-39-3|Palifosfamide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Palifosfamide |
|---|
| CAS Number | 31645-39-3 | Molecular Weight | 221.022 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 341.5±52.0 °C at 760 mmHg |
|---|
| Molecular Formula | C4H11Cl2N2O2P | Melting Point | 106-107ºC |
|---|
| MSDS | / | Flash Point | 160.4±30.7 °C |
|---|
Names
| Name | Palifosfamide |
|---|
| Synonym | More Synonyms |
|---|
Palifosfamide BiologicalActivity
| Description | Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity. |
|---|
| Related Catalog | Signaling Pathways >>Cell Cycle/DNA Damage >>DNA Alkylator/CrosslinkerResearch Areas >>Cancer |
|---|
| In Vitro | Palifosfamide lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro. The IC50 ranges from 2.25 ro 6.75 μM for most cell lines except OS222 (IC50=31.5 μM)[1]. |
|---|
| In Vivo | Tumor growth inhibition is seen in both OS31 and OS33 xenografts and the RMS xenograft resulting in a significant difference in event-free survival between the control and the treated groups. Differential gene expression of ALDH3A1 but not ALDH1A1 is noted in the OS31 xenograft[1]. Stabilized palifosfamide administered to mice suppresses MX-1 tumor growth by greater than 80% with 17% complete antitumor responses. Oral bioavailability in rats is 48-73% of parenteral administration, and antitumor activity in mice is equivalent by both routes. Treatment with palifosfamide-tris combined with docetaxelor doxorubicin at optimal regimens results in complete tumor regression in 62-75% of mice[2]. |
|---|
| Cell Assay | Palifosfamide is dissolved in phosphate buffered saline (PBS). Cells are plated in 96-well microtiter plates with approximately 500 cells per well in 100 μL of media. After 24 h of incubation at 37°C, cells are treated with increasing concentrations of palifosfamide lysine in separate plates either as a single-day treatment or three consecutive days of treatment, with fresh drug being added each day. The plates are incubated for 72 h at 37°C with 5% CO2. After 72 h, 250 μg of MTT is added to each well and incubated at 37°C for 6 h. MTT is converted to formazine crystals by mitochondria of viable cells, which are then dissolved in 100 μL of dimethyl sulfoxide. Optical density is measured at 595 nm[2]. |
|---|
| Animal Admin | Mice: CB17 female SCID mice are used in the study. Once the tumors reached 50–150 mm3, mice are randomized into control and treatment groups (5-8 mice/group) for each tumor line. Cyclophosphamide is administered at the dose of 150 mg/kg intraperitoneally once a week for 6 weeks. Palifosfamide lysine is administered intravenously at the maximum tolerated dose of 100 mg/kg for three consecutive days as a one-time treatment and serial tumor volumes are determined over the next 6 weeks. Mice are sacrificed at the end of the experiment[2]. |
|---|
| References | [1]. Hingorani P, et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009 Sep;64(4):733-40. [2]. Jones B, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 341.5±52.0 °C at 760 mmHg |
|---|
| Melting Point | 106-107ºC |
|---|
| Molecular Formula | C4H11Cl2N2O2P |
|---|
| Molecular Weight | 221.022 |
|---|
| Flash Point | 160.4±30.7 °C |
|---|
| Exact Mass | 219.993515 |
|---|
| PSA | 71.17000 |
|---|
| LogP | -1.05 |
|---|
| Appearance of Characters | white solid |
|---|
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
|---|
| Index of Refraction | 1.498 |
|---|
| InChIKey | BKCJZNIZRWYHBN-UHFFFAOYSA-N |
|---|
| SMILES | O=P(O)(NCCCl)NCCCl |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| Phosphorodiamidic acid, N,N'-bis(2-chloroethyl)- |
| Isophosphamide mustard |
| Ipam |
| Ifosforamide mustard |
| N,N'-Bis(2-chloroethyl)phosphorodiamidic acid |
| ifosfamide mustard |
| isophosphoramide mustard |
| isophosphoramide |
| isophpsphoramide mustard |
| Palifosfamide |
